View Older Stories View More Recent Stories

Feb 13, 2024 07:01PM Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2024 04:43PM Eledon Pharmaceuticals (ELDN) Highlights Recent Business Milestones, Provides 2024 Outlook
Jan 4, 2024 04:40PM Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Dec 4, 2023 06:00PM Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29, 2023 04:05PM Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Nov 29, 2023 04:05PM Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Nov 9, 2023 04:01PM Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Nov 8, 2023 04:05PM Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
Nov 2, 2023 09:06AM Eledon Pharmaceuticals (ELDN) Reports Updated Data from Ongoing Phase 1b Trial of Tegoprubart
Nov 2, 2023 09:05AM Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Oct 23, 2023 07:01AM Eledon Pharmaceuticals (ELDN) Appoints Eliezer Katz as Chief Medical Officer
Oct 23, 2023 07:00AM Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
Oct 13, 2023 07:00AM Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Oct 2, 2023 07:07AM Eledon Pharmaceuticals (ELDN) Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
Oct 2, 2023 07:00AM Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
Sep 25, 2023 07:03AM Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
Sep 25, 2023 07:00AM Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
Sep 20, 2023 04:05PM Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2023 07:02AM Eledon Pharmaceuticals (ELDN) Appoints James Robinson to its Board
Sep 11, 2023 07:00AM Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
Sep 6, 2023 07:00AM Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
Sep 5, 2023 07:00AM Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
Aug 16, 2023 07:00AM Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
Aug 10, 2023 07:00AM Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Jun 2, 2023 08:00AM Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
May 11, 2023 04:01PM Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
May 4, 2023 04:05PM Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 1, 2023 07:03AM Eledon Pharmaceuticals (ELDN) Announces up to $185M Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
May 1, 2023 07:02AM Eledon Pharmaceuticals (ELDN) Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
May 1, 2023 07:00AM Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
May 1, 2023 07:00AM Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
Mar 31, 2023 06:01AM Eledon Pharmaceuticals (ELDN) Reports Data from Ongoing Phase 1b Trial of Tegoprubart
Mar 31, 2023 06:00AM Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
Mar 31, 2023 06:00AM Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
Mar 30, 2023 04:01PM Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
Mar 30, 2023 04:01PM Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
Mar 23, 2023 04:05PM Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
Mar 23, 2023 04:05PM Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
Mar 23, 2023 08:03AM Eledon Pharmaceuticals (ELDN) to Present Data from Ongoing Phase 1b Trial of Tegoprubart
Mar 23, 2023 08:00AM Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Mar 23, 2023 08:00AM Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Feb 8, 2023 04:05PM Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
Feb 8, 2023 04:05PM Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
Jan 9, 2023 08:31AM Eledon Pharmaceuticals Provides Business and Pipeline Updates
Jan 9, 2023 08:31AM Eledon Pharmaceuticals Provides Business and Pipeline Updates
Dec 21, 2022 04:05PM C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
Nov 14, 2022 04:01PM Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
Nov 14, 2022 04:01PM Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
Nov 3, 2022 04:05PM Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Nov 3, 2022 04:05PM Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
View More Recent Stories View Older Stories